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ases encoded by the human genome 
(Schofield and Ratcliffe, 2004). Other 
2-oxoglutarate-dependent dioxygen-
ases that have credible roles in cancer 
biology include those with long-estab-
lished functions in extracellular matrix 
formation, such as procollagen prolyl 
and lysyl hydroxylases, and those with 
recently established functions in his-
tone demethylation (Shi and Whetstine, 
2007). Thus, it remains conceivable that 
HIF activation is a marker rather than 
the cause of oncogenic predisposition 
and/or that different types of tumor 
predisposition reflect effects on differ-
ent enzyme/substrate systems. Either 
way, the new findings open a range of 
possible insights into the association of 
hypoxia and cancer progression.
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Synovial sarcoma is characterized by the presence of a fusion protein involving SYT and SSX2. In 
this issue of Cancer Cell, Haldar et al. have genetically engineered a mouse model of this disease. 
They show that expression of the SYT-SSX2 fusion gene yields a highly penetrant and representative 
model of human synovial sarcoma, but only if expression occurs in a particular biologic context. The 
mouse model will be a valuable resource for studying tumor biology but is also a striking example of 
how important understanding of normal tissue and developmental biology is to our understanding 
of cancer.Sarcomas comprise a diverse 
group of malignant tumors of mes-
enchymal origin, arising in connec-
tive tissues such as fat, muscle, 
fibrous tissue, and bone (Helman 
and Meltzer, 2003). These tumors 
are relatively rare, with an annual 
incidence of seven to eight per 
100,000. They account for less than 
1% of all malignancies overall, but 
about 15% of malignancies in chil-
dren. Sarcomas have historically 
been classified based on their site 
of origin, morphology, and immuno-histochemical properties. Although 
some sarcomas can be classified 
easily according to these criteria 
and their clinical features, many 
present significant diagnostic chal-
lenges. However, more recently, 
many soft-tissue sarcomas have 
been shown to carry recurrent, 
characteristic chromosomal trans-
locations, several of which gener-
ate fusion proteins that act as tran-
scription factors (Table 1) (Mackall 
et al., 2002). As in leukemia and 
lymphoma, these causative genetic Cancer Ceevents provide a point of departure 
for sarcoma researchers. Impor-
tantly, the translocations are likely 
to reveal biological mechanisms 
whose importance transcends the 
rarity of these diseases. However, 
despite the opportunities provided 
by the discovery of sarcoma trans-
locations, biological understanding 
of many sarcomas remains limited. 
The rarity of sarcomas and their 
clinical heterogeneity, even within 
a single histologic classification, 
present the greatest obstacles. ll 11, April 2007 ©2007 Elsevier Inc. 305
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PreviewsTable 1. Chromosomal Translocations Resulting in Fusion Genes in Sarcomas
Tumor Translocation Fusion Gene
Synovial sarcoma t(X;18)(p11;q11) SYT-SSX (1, 2, or 4)*
complex rearrangements SS18L1-SSX1*
Ewing’s sarcoma t(11;22)(q24;q12) EWSR1-FLI1*
t(21;22)(q22;q12) EWSR1-ERG*
t(7;22)(p22;q12) EWSR1-ETV1*
t(17;22)(q21;q12) EWSR1-ETV4*
t(2;22)(q33;q12) EWSR1-FEV*
Clear-cell sarcoma t(12;22)(q13;q12) EWSR1-ATF1*
Desmoplastic small round cell tumor t(11;22)(p13;q12) EWSR1-WT1*
Myxoid chondrosarcoma t(9;22)(q22-31;q11-12) EWSR1-NR4A3*
t(9;17)(q22;q11.2) TAF15-NR4A3*
Myxoid liposarcoma t(12;16)(q13;p11) FUS-DDIT3*
t(12;22)(q13;q12) EWSR1-DDIT3*
Alveolar rhabdomyosarcoma t(2;13)(q35;q14) PAX3-FOXO1A*
t(1;13)(p36;q14) PAX7-FOXO1A*
Dermatofibrosarcoma protuberans t(17;22)(q22;q13) COL1A1-PDGFB
Congenital fibrosarcoma t(12;15)(p13;q25) ETV6-NTRK3
Inflammatory myofibroblastic tumor 2p23 rearrangements TMP3-ALK
TMP4-ALK
Alveolar soft part sarcoma t(X;17)(p11.2;q25) ASPL-TFE3*
Endometrial stromal sarcoma t(7;17)(p15;q21) JAZF1-SUZ12*
Low-grade fibromyxoid sarcoma t(7;16)(q33;p11) FUS-CREB3L2*
Angiomatoid fibrous histiocytoma t(12;22)(q13;q12) EWSR1-ATF1*
complex rearrangements FUS-ATF1*
Asterisks indicate fusion genes that encode transcription factors or cofactors.Additionally, for most sarcomas, 
cell line resources are also limited 
and, as for any cancer type, do not 
fully recapitulate the biology of the 
in vivo tumor. Animal models pres-
ent a very appealing solution to sev-
eral of these problems, particularly 
in the sarcomas that exhibit recur-
rent translocations. By introducing 
the fusion gene into an animal, one 
could hope to accurately model the 
disease process. A successful ani-
mal model could overcome many of 
the obstacles to the study of these 
rare cancers, allowing detailed 
investigation into the mechanism of 
tumorigenesis as well as providing 
a platform for experimental thera-
peutics. However, despite their his-
tologic similarity to adult tissues, 
the cell of origin for many sarco-306 Cancer Cell 11, April 2007 ©2007 Elsmas remains ill-defined or totally 
unknown, significantly complicating 
the genetic engineering of such ani-
mal models. Furthermore, the timing 
and context of the expression of the 
fusion protein play an important role 
in the fusion protein’s phenotypic 
effect. For these reasons, progress-
ing from the discovery of a sarcoma 
fusion protein to construction of an 
animal model has proved to be chal-
lenging, though not without some 
success (Keller et al., 2004; Riggi et 
al., 2005).
Synovial sarcoma (SS) is a rela-
tively frequent, highly aggressive 
sarcoma that occurs in both children 
and adults. It tends to arise adja-
cent to joints in the limbs—hence the 
name (the tissue that lines joints is 
called the synovium). However, this evier Inc.is a historically based misnomer; SS 
is not related to synovial tissue at 
all and is known to occur in sites far 
from joints, such as the thorax. SS 
is currently classified as a tumor of 
uncertain differentiation with no clear 
resemblance to any normal tissue. 
Morphologically, SS has two common 
subtypes, monophasic and biphasic, 
which are characterized by predomi-
nantly spindle cells or by a mixture of 
spindle cells and cells with epithelial 
differentiation, respectively. SS is 
characterized by a recurrent translo-
cation [t(X;18)(p11;q11)] that leads to 
production of a fusion protein (Clark 
et al., 1994) (Table 1). In the vast 
majority of SS, the SYT (SS18) gene 
on chromosome 18 is fused with 
one of two closely related genes on 
chromosome X, SSX1 or SSX2. The 
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sarcoma fusions in that this nuclear 
protein lacks a direct DNA-bind-
ing domain and appears to act as a 
transcriptional coregulator. Precisely 
how SYT-SSX transforms the nor-
mal progenitor of SS into sarcoma is 
unknown but is likely to depend on 
perturbation of normal gene expres-
sion at the chromatin level (de Bruijn 
et al., 2007).
In this issue of Cancer Cell, Hal-
dar et al. present a mouse model of 
SS engineered from an SYT-SSX2 
fusion construct derived from an SS 
patient (Haldar et al., 2007). Through 
elegant use of genetic techniques, 
the authors produced a mouse that, 
with 100% penetrance, produces 
tumors that recapitulate many of the 
most important aspects of SS biol-
ogy, including anatomic distribution, 
morphology, and gene expression. 
The authors capitalized on knowl-
edge of developmental biology to tar-
get the expression of the SYT-SSX2 
fusion transcript to specific develop-
mental stages in a particular tissue, 
skeletal muscle, which they posit 
could be the cell of origin for SS. By 
inserting an inactive SYT-SSX2 fusion 
at the ROSA26 locus, viable mice 
were obtained whose progeny only 
express the fusion gene in crosses 
with Cre recombinase-expressing 
animals. Haldar et al. were thus able 
to target SYT-SSX2 expression to 
specific stages of muscle develop-
ment by crossing the SYT-SSX2 mice 
with strains that express Cre under 
the control of promoters that are 
active at specific stages of muscle 
development. The success of this 
strategy transforms the field of syno-
vial sarcoma research from one ham-
pered by the progenitor cell mystery 
to one that could take advantage of 
the extensive knowledge of skeletal muscle development, one of the best 
understood developmental systems.
Of the muscle promoters tested, 
Haldar et al. demonstrate that only 
Myf5-Cre leads to the development 
of SS tumors. Expressing Cre under 
the control of an ubiquitous pro-
moter (Hprt) or early muscle lineage 
promoters (Pax3 or Pax7) results 
in embryonic lethality, while Myf6 
results in myopathy. The authors 
also suggest an interesting possi-
bility deserving of further investiga-
tion, that the association of SS with 
joints may be related to specific 
factors in the microenvironment 
that promote survival of SYT-SSX2-
expressing cells. These striking 
observations illustrate the critical 
importance of the timing of fusion 
transcript expression and illuminate 
the extent to which fusion oncop-
rotein action is restricted by devel-
opmental and cellular context. Only 
fusion protein expression under 
the specific developmental stage 
characterized by MYF5 expression 
leads to cancer. This is interesting 
both for SS, by providing evidence 
that human SS may derive from the 
myogenic lineage, and for sarcoma 
translocation biology in general, by 
establishing the remarkable speci-
ficity required for the development 
of a translocation-dependent sar-
coma. What accounts for the great 
tumor specificity of translocations, 
which presumably occur at random 
in many cell types? One widely dis-
cussed possibility, now elegantly 
modeled in SS, is that only spe-
cific cell types are susceptible to 
the transforming effects of a given 
translocation that may reduce fit-
ness or even cause lethality in most 
cell types. Further biologic insights 
are sure to arise from this model, 
which because of the high pene-Cancer Cetrance of the SS phenotype will pro-
vide a tremendous opportunities to 
advance SS research. Of particular 
interest will be the search for “sec-
ond hits,” genetic events that must 
occur in addition to SYT-SSX2 to 
produce a malignant tumor. Also 
of general interest and quite timely 
are the opportunities generated by 
this model to explore the relation 
between chromatin function and 
cancer. Alterations of other genes 
that, like SYT-SSX2, regulate gene 
expression at the chromatin level 
are known to be associated with 
other solid tumors (e.g., SMARCB1) 
and leukemia (e.g., MLL-associated 
leukemias). More generally, this 
systematic approach to generating 
models might be applied to other 
sarcoma translocations. Refined 
tools for targeting translocations to 
specific cell populations at discrete 
developmental stages clearly have 
the potential to accomplish these 
difficult tasks.
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